{
    "title": "Teva hires ex-Novartis executive to succeed CEO Schultz",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11453015/Teva-hires-ex-Novartis-exec-succeed-CEO-Schultz.html",
    "date": "2022-11-21",
    "keywords": [
        "drug",
        "francis",
        "schultz",
        "company",
        "teva",
        "debt",
        "bhanvi",
        "satija",
        "biogen",
        "business",
        "launch",
        "companys",
        "sclerosis",
        "monday",
        "novartis",
        "executive",
        "richard",
        "officer",
        "kare",
        "year",
        "post",
        "gene",
        "therapy",
        "firm",
        "role",
        "president",
        "jan",
        "chief",
        "tecfidera",
        "appointment",
        "risperidone",
        "lai",
        "biosimilar",
        "amgen",
        "humira",
        "experience",
        "core",
        "specialty",
        "analyst",
        "tenure",
        "loss",
        "patent",
        "blockbuster",
        "copaxone",
        "price",
        "fixing",
        "opioid",
        "settlement",
        "drugmaker",
        "morning",
        "trade",
        "lundbeck",
        "predecessor",
        "erez",
        "vigodman",
        "move",
        "workforce",
        "shut",
        "stock",
        "market",
        "cap",
        "peak",
        "august",
        "reporting",
        "khushi",
        "mandowara",
        "bengaluru",
        "scheer",
        "jerusalem",
        "editing",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}